AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions

Leukemia, Myeloid, Chronic

Interventions

DRUG

Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.

Trial Locations (13)

Birmingham

La Jolla

Los Angeles

Denver

Farmington

Chicago

Boston

St Louis

New York

Portland

Pittsburgh

Liverpool

London